Clinical Trials Browser

Phase 1 × asparaginase erwinia chrysanthemi recombinant × 90 days × Clear all

NCT07133997 2026-04-07

Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia

Phase 1 Recruiting

Burkitt Lymphoma